SLC-391

Overview

SLC-391 is an orally active AXL kinase inhibitor with an IC 50 of 9.6 nM against AXL kinase. SLC-391 inhibits Gas6-induced AXL-dependent phosphorylation of Akt . SLC-391 inhibits SARS-CoV-2 infection , entry and replication in cells. SLC-391 suppresses cancer cell proliferation. SLC-391 inhibits tumor growth in mouse solid tumor xenograft models. SLC-391 can be used for the research of COVID-19, influenza virus infection, triple-negative breast cancer , chronic myeloid leukemia and non-small cell lung cancer .

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > TAM Receptor | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-177332
• CAS No.: 1783825-18-2
• Molecular Formula: C19H23N7O
• Molecular Weight: 365.43
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source